Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 131

Sort by

Sort Order Select

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

Evaluation of the Human Factor IX Gene Therapy Vector TAK-748 in Hemophilia: Results from Non-Clinical Studies in Factor IX Knockout Mice and Rhesus Monkeys

Markus Weiller, Helen Wang, Sogué Coulibaly, Maria Schuster, Hanspeter Rottensteiner, Kefeng Sun, Marinee K Chuah, Thierry Vandendriessche, Friedrich Scheiflinger, Werner Höllriegl

Blood (2019) 134 (Supplement_1): 4633.

https://doi.org/10.1182/blood-2019-124734

Published: 2019

Journal Articles

Use of Fluid and Oxygen Therapy in Normoaxaemic Paediatric Patients Presenting with Acute Sickle Vaso-Occlusive Episodes Requiring Hospital Admission and Analysis of Clinical Outcome

Zain Butt, BSc, Subarna Chakravorty, PhDFRCPath MRCP MRCPCH

Blood (2019) 134 (Supplement_1): 4844.

https://doi.org/10.1182/blood-2019-125708

Published: 2019

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study

Philippe Moreau, David S Siegel, MD PhD, Hartmut Goldschmidt, MD, Ruben Niesvizky, MD, Sara Bringhen, MD, Robert Z Orlowski, MD PhD, Julie Blaedel, Zhao Yang, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2018-99-112571

Published: 2018

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (activated) an Engineered FVIIa in Hemophilia with Inhibitors - Pharmacokinetics, Pharmacodynamics, Safety and Efficacy

Howard Levy, PhD MBBChir, Levani Makhaldiani, Genadi Iosava, MD, Johnny Mahlangu, Marina V Kosinova, MD, Heghine Khacchatryan, MD, Frank Del Greco, MBA, Frank V. McL. Booth, MA MSc BM BCh

Blood (2018) 132 (Supplement 1): 1198.

https://doi.org/10.1182/blood-2018-99-112567

Published: 2018

Journal Articles

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Blood (2017) 130 (Supplement 1): 567.

https://doi.org/10.1182/blood.V130.Suppl_1.567.567

Published: 2017

Journal Articles

Protein C Infusion Therapy in an Adult Case of Severe Congenital Protein C Deficiency

Shuoyan Ning, MD, Eric Tseng, MD, Mark Crowther, MD

Blood (2017) 130 (Supplement 1): 4916.

https://doi.org/10.1182/blood.V130.Suppl_1.4916.4916

Published: 2017

Journal Articles

The Anti-Factor XII Antibody AB052 Is Antithrombotic without Hemostatic Impairment in a Primate Model of Extracorporeal Membrane Oxygenation

Michael Wallisch, PhD, Erik I Tucker, PhD, Christina U Lorentz, PhD, Jennifer Johnson, RLATG, Marschelle R Carris, BA, Owen JT McCarty, PhD, Monica T Hinds, PhD, András Gruber, MD

Blood (2017) 130 (Supplement 1): 236.

https://doi.org/10.1182/blood.V130.Suppl_1.236.236

Published: 2017

Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lucy DeCosta, MSc, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, MD, Xavier Leleu, MD PhD

Blood (2017) 130 (Supplement 1): 3120.

https://doi.org/10.1182/blood.V130.Suppl_1.3120.3120

Published: 2017

Journal Articles

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Karim Saad Iskander, Xavier Leleu, MD PhD

Blood (2017) 130 (Supplement 1): 1840.

https://doi.org/10.1182/blood.V130.Suppl_1.1840.1840

Published: 2017

Journal Articles

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Sarah Bertoli, MD PhD, Noemie Gadaud, Suzanne Tavitian, MD, Audrey Sarry, Emilie Bérard, MD PhD, Françoise Huguet, MD, Christian Recher, MD PhD

Blood (2016) 128 (22): 3991.

https://doi.org/10.1182/blood.V128.22.3991.3991

Published: 2016

Journal Articles

Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys

Suzette Girgis, PhD BPharm, MS, Shoba Shetty, PhD, Trina Jiao, MS, Chidozie Amuzie, Dan Weinstock, Rebecca Grimme Watson, Joyce Ford, Kodandaram Pillarisetti, Eric Baldwin, Kevin Bellew

Blood (2016) 128 (22): 5668.

https://doi.org/10.1182/blood.V128.22.5668.5668

Published: 2016

Journal Articles

24-Hour Profile of Microvascular Liver Perfusion in Sickle Cell Disease Mice Following Hypoxia-Induced Vaso-Occlusion

Keith Abe, B.S., Michael Wright, B.S., Derek Sim, PhD, Magdalena Alonso-Galicia, PhD, Katalin Kauser

Blood (2016) 128 (22): 1300.

https://doi.org/10.1182/blood.V128.22.1300.1300

Published: 2016

Journal Articles

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Daniel W. Sherbenou, MD PhD, Blake T. Aftab, PhD, Yang Su, PhD, Christopher R. Behrens, PhD, Arun P. Wiita, MD PhD, Aaron C. Logan, MD PhD, Diego Acosta-Alvear, PhD, Byron C. Hann, MD PhD, Peter Walter, PhD, Xiaobo Wu, MD, John P. Atkinson, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Bin Liu, PhD

Blood (2016) 128 (22): 384.

https://doi.org/10.1182/blood.V128.22.384.384

Published: 2016

Journal Articles

Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group

Evangelos Terpos, Eirini Katodritou, Argiris Symeonidis, Flora Zagouri, Antonis Gerofotis, Georgia Christopoulou, Maria Gavriatopoulou, Dimitrios Christoulas, Alexandra Kourakli, Pavlina Konstantinidou, Efstathios Kastritis, MD, Meletios A Dimopoulos

Blood (2016) 128 (22): 4488.

https://doi.org/10.1182/blood.V128.22.4488.4488

Published: 2016

Journal Articles

Effect of Dexrazoxane on Heart Function Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG)

Eric J Chow, MD MPH, David R. Doody, MS, Saro H. Armenian, DO, MPH, Sanjeev Aggarwal, MD, K. Scott Baker, MD MS, Smita Bhatia, MD MPH, Nancy A. Blythe, BA, Louis S. Constine, MD, David R. Freyer, DO, MS, Lisa M. Kopp, DO, Wendy M. Leisenring, ScD, Nao Sasaki, MD, Lynda M. Vrooman, MD MSc, Barbara L. Asselin, MD, Cindy L. Schwartz, MD MPH, Steven E. Lipshultz, MD FAAP, FAHA

Blood (2016) 128 (22): 696.

https://doi.org/10.1182/blood.V128.22.696.696

Published: 2016

Journal Articles

A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Satyaprakash Nayak, PhD, Dooyoung Lee, PhD, Steven Arkin, MD, Steven W. Martin, PhD, Anne C. Heatherington, PhD, William S. Denney, PhD, Paolo Vicini, PhD, Fei Hua, PhD

Blood (2015) 126 (23): 3502.

https://doi.org/10.1182/blood.V126.23.3502.3502

Published: 2015

NARROW

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Evaluation of the Human Factor IX Gene Therapy Vector TAK-748 in Hemophilia: Results from Non-Clinical Studies in Factor IX Knockout Mice and Rhesus Monkeys

Use of Fluid and Oxygen Therapy in Normoaxaemic Paediatric Patients Presenting with Acute Sickle Vaso-Occlusive Episodes Requiring Hospital Admission and Analysis of Clinical Outcome

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (activated) an Engineered FVIIa in Hemophilia with Inhibitors - Pharmacokinetics, Pharmacodynamics, Safety and Efficacy

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Protein C Infusion Therapy in an Adult Case of Severe Congenital Protein C Deficiency

The Anti-Factor XII Antibody AB052 Is Antithrombotic without Hemostatic Impairment in a Primate Model of Extracorporeal Membrane Oxygenation

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys

24-Hour Profile of Microvascular Liver Perfusion in Sickle Cell Disease Mice Following Hypoxia-Induced Vaso-Occlusion

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group

Effect of Dexrazoxane on Heart Function Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG)

A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only